Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib
Max J. Gordon(Oregon Health & Science University), Alexey V. Danilov(City of Hope), Jonathon B. Cohen(Emory University), Michael C. Churnetski(Emory University), Hamood Alqahtani(University of California San Diego), Stephen M. Amrock(Oregon Health & Science University), Spencer James(Dartmouth–Hitchcock Medical Center), Xavier Rivera(University of Arizona), Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Daniel O. Persky(Universidad San Carlos), Michael Y. Choi(University of California San Diego), Sheila Hoff(University of California San Diego), Sudhir Manda(Dartmouth–Hitchcock Medical Center), Stephen E. Spurgeon(Oregon Health & Science University)
Cited by 86
Related Papers
Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015
|The Lancet|2017|2.1k
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2017|378
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
|The Lancet Oncology|2017|327